FoLix™ Recognized for Dermatology Innovation in 2025 MedTech Breakthrough Awards Program
Lumenis is proud to announce that FoLix™, the innovative hair loss treatment by Lumenis, has been honored with the “Best New Dermatology Technology Solution” award at the 2025 MedTech Breakthrough Awards.
This groundbreaking solution is the first FDA-cleared non-ablative fractional laser for hair loss, delivering results in just 4-6 monthly sessions with minimal discomfort and no downtime.
The awards’ judging panel selected FoLix as the winner of this competitive category due to its combination of scientific innovation, patient-centric design and measurable clinical impact.
According to MedTech, FoLix fills a critical gap in the dermatology space and also offers a truly novel, non-invasive option for patients seeking meaningful results – making FoLix a standout among this year’s dermatology technology innovations. The judges were particularly impressed by FoLix’s ability to apply the regenerative power of fractional laser technology to a new frontier: hair follicle stimulation.
The award underscores Lumenis’ significant contribution to the fields of dermatology and technological innovation.
Tzipi Ozer-Armon, CEO of Lumenis, stated that FoLix represents a significant advancement in hair treatment, addressing lifestyle needs while enhancing confidence and beauty. The MedTech Breakthrough Awards program celebrates excellence and innovation across medical technology sectors, showcasing transformative solutions like FoLix.
The MedTech Breakthrough Awards program celebrates excellence and innovation in the health and medical technology industry, recognizing the companies, products, and solutions driving meaningful progress and improving patient care.
For more information about FoLix please visit Lumenis.com/FoLix
About FoLix™
FoLix™ is a non-ablative fractional laser device to improve the appearance of scalp hair in adult males and females with Fitzpatrick skin types I to IV, who are seeking treatment for hair loss.
FoLix treatment could cause redness, swelling, scarring, damage to natural skin texture (e.g. blisters), fragile skin, burns, hair shedding, itching, and pigmentation change. The use of FoLix is contraindicated for patients with any concurrent cancer or history of skin cancer, or pre-cancerous lesions at the treatment area, active infection, chronic fungal or bacterial diseases or chronic dermatological condition of the scalp. See the system user manual for a complete list of contraindications and risks.
DOWNLOAD FoLix BROCHURE
PB-00088280 Rev A